AstraZeneca to pay $775 mln to settle ALS drug dispute
17/03/2022 07:12
March 17 (Reuters) - British drugmaker AstraZeneca Plc
AZN.L will pay $775 million to settle a patent dispute with
Japan's Chugai Pharmaceutical Co Ltd 4519.T related to the ALS
drug Ultomiris, it said on Thursday.
The settlement would not affect AstraZeneca's financial
forecasts for 2022, it said.
(Reporting by Sachin Ravikumar in Bengaluru; Editing by Rashmi
Aich)
((saisachin.r@tr.com; +91 80 6182 2754; Twitter: @sachinr27;))
Recent news on Chugai Pharmaceutical
See all newsRegarding Discontinuation Of Development Of Gym329 (Emugrobart) For Obesity, Return Of License And Resumption Of Development For SMA
Table: Chugai Pharm 6-MTH group results (IFRS)
Japan's Nikkei roars past 62,000 on earnings, Middle East optimism; JGBs rally (updated)
Japan's Nikkei surges past 61,000 for first time on earnings, Mideast optimism
Japan's Nikkei closes above 60,000 for first time on earnings optimism (updated)